List of Excipients in Branded Drug CIDOFOVIR

Generic Drugs Containing CIDOFOVIR

Company	Ingredient	NDC	Excipient
Mylan Institutional LLC	cidofovir anhydrous	67457-210	HYDROCHLORIC ACID
Mylan Institutional LLC	cidofovir anhydrous	67457-210	SODIUM HYDROXIDE
Mylan Institutional LLC	cidofovir anhydrous	67457-210	WATER
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	cidofovir dihydrate	23155-216	HYDROCHLORIC ACID
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	cidofovir dihydrate	23155-216	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in CIDOFOVIR?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE
1	WATER

Cidofovir Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Cidofovir is an FDA-approved intravenous antiviral with a formulation profile shaped by three constraints: high polarity, poor oral absorption, and dose-limiting nephrotoxicity. The commercial opportunity is therefore concentrated in safer delivery systems, local formulations, pediatric and specialty products, and prodrugs rather than in simple excipient substitution. The strongest product concepts reduce renal exposure, improve tissue targeting, or eliminate the need for intravenous administration.

What is cidofovir, and how is it currently formulated?

Cidofovir is an acyclic nucleoside phosphonate antiviral marketed in the United States as Vistide for intravenous treatment of cytomegalovirus retinitis in patients with AIDS and without adequate renal function at baseline. The FDA-approved product contains cidofovir dihydrate at a concentration equivalent to 75 mg/mL of anhydrous cidofovir. It is supplied in a single-dose vial and is administered after dilution in 100 mL of 0.9% sodium chloride injection.[1]

Product attribute	Current Vistide profile
Active ingredient	Cidofovir, supplied as cidofovir dihydrate
Dosage form	Intravenous concentrate
Strength	75 mg/mL
Diluent	100 mL of 0.9% sodium chloride injection
pH adjustment	Sodium hydroxide and hydrochloric acid
Preservatives	No preservative is identified in the FDA label
Required co-therapy	Probenecid and intravenous hydration
Approved indication	CMV retinitis in patients with AIDS
Major safety constraint	Nephrotoxicity
Administration burden	Intravenous infusion, hydration, laboratory monitoring, and probenecid dosing

Cidofovir has a phosphonate group that remains highly ionized under physiological conditions. This gives the molecule antiviral activity after intracellular phosphorylation but limits passive membrane permeation and oral absorption. Renal tubular uptake and accumulation contribute to nephrotoxicity.[1,2]

The commercial formulation problem is therefore broader than solubility. A successful product must address one or more of the following:

1. Reduce renal tubular exposure.
2. Improve intracellular delivery.
3. Increase local concentration at infected tissue.
4. Reduce infusion and hydration requirements.
5. Improve patient adherence.
6. Preserve chemical stability during manufacturing and storage.

What excipients are used in the approved cidofovir injection?

The approved formulation uses a minimal excipient system. The FDA label identifies sodium hydroxide for pH adjustment and hydrochloric acid for pH adjustment. The product is diluted with 0.9% sodium chloride before administration.[1]

Excipient functions

Excipient or vehicle	Function	Commercial relevance
Sodium hydroxide	Adjusts formulation pH and contributes to cidofovir solubilization in the ionized state	Supports a simple aqueous formulation
Hydrochloric acid	Final pH adjustment	Helps control product pH and stability
Water for injection	Primary vehicle in the concentrate	Enables parenteral administration
0.9% sodium chloride	Infusion diluent	Limits bedside preparation to a familiar hospital vehicle
Probenecid	Renal-protective co-therapy, not a formulation excipient	Creates a combined-treatment burden
Intravenous fluids	Hydration regimen, not a formulation excipient	Increases administration time and resource use

The Vistide label instructs dilution in 100 mL of 0.9% sodium chloride. The diluted solution should be administered by infusion over one hour. The label also requires probenecid and saline hydration because cidofovir can cause serious renal injury.[1]

The formulation strategy is intentionally conservative. It avoids surfactants, complexing agents, cosolvents, and particulate delivery systems. That simplicity reduces manufacturing and compatibility risk but leaves substantial room for differentiated products.

What excipient strategies could improve cidofovir delivery?

The most attractive excipient strategies are those that alter tissue distribution or localize cidofovir without increasing systemic exposure.

1. Mucoadhesive topical systems

Cidofovir has been compounded for topical use in conditions such as cutaneous viral lesions, including refractory human papillomavirus-associated lesions and other viral skin diseases. These preparations have included creams, gels, and compounded solutions, but they are not equivalent to an FDA-approved cidofovir topical product.[3,4]

Potential excipient classes include:

• Carbomers and polyacrylic acid polymers
• Hydroxypropyl methylcellulose
• Hydroxyethyl cellulose
• Poloxamers
• Cellulose ethers
• Chitosan
• Polyethylene glycol and propylene glycol systems
• Lipid or emulsion vehicles

A commercial topical product would need to demonstrate reproducible drug release, adequate lesion penetration, low systemic absorption, acceptable local tolerability, and microbiological control. A mucoadhesive gel could improve residence time on mucosal lesions, while a film-forming system could increase contact with external lesions.

The main regulatory risk is dose reproducibility. Extemporaneous formulations vary in vehicle composition, drug loading, pH, particle size, and packaging. A commercial product could compete by providing validated potency, uniformity, stability, and a defined application device.

2. Nanoparticle and liposomal systems

Liposomal or polymeric carriers could reduce exposure of free cidofovir to renal tubular cells and increase delivery to macrophages, epithelial tissue, or infected mucosa. Candidate excipients include phospholipids, cholesterol, ionizable lipids, biodegradable polyesters, and surface-modifying polymers.

The advantage is pharmacokinetic differentiation. The risks include:

• Low drug loading because cidofovir is highly hydrophilic
• Leakage during storage
• Difficult scale-up
• Sterilization constraints
• Batch-to-batch particle-size variation
• New toxicology requirements for the carrier
• Complex regulatory characterization

A nanoparticle product is more likely to justify development where cidofovir has a high unmet need and systemic administration is impractical. It is less attractive for routine CMV retinitis treatment if a lower-complexity prodrug or local product can achieve the same objective.

3. In situ gels and ocular delivery systems

Cidofovir has been investigated in ophthalmic and ocular settings, but ocular delivery presents a narrow therapeutic window. A product must achieve antiviral concentrations without producing corneal, conjunctival, or intraocular toxicity.

Useful excipient approaches include:

• Thermoresponsive polymers
• Mucoadhesive polymers
• In situ gelling systems
• Cyclodextrin-based solubilization
• Preservative-free multidose systems
• Ocular inserts or sustained-release depots

An ocular product could reduce dosing frequency and improve retention compared with conventional drops. However, the development burden is high because ocular safety, sterility, extractables, container closure, and local tolerability become central issues.

4. Oral and targeted prodrug systems

Excipient optimization alone is unlikely to overcome cidofovir’s poor oral bioavailability. The more commercially important strategy has been chemical prodrug design. Brincidofovir, an orally administered lipid conjugate of cidofovir, was developed to improve oral absorption and intracellular delivery while reducing the renal toxicity associated with intravenous cidofovir.[5]

Brincidofovir demonstrates the commercial value of changing the active pharmaceutical ingredient rather than relying solely on excipients. A formulation company could still pursue oral delivery using lipid-based systems, permeation-enhancing excipients, or enteric protection, but the commercial case must compete against prodrug approaches with stronger pharmacokinetic advantages.

Which dosage forms offer the strongest commercial opportunities?

Dosage form	Opportunity	Development attractiveness	Principal barrier
Improved IV concentrate	Moderate	Low to moderate	Limited differentiation from existing aqueous product
Ready-to-use IV bag	Moderate	Moderate	Stability, container compatibility, hospital demand
Topical cream or gel	High for niche viral lesions	Moderate	Clinical evidence and compounded-use competition
Mucoadhesive mucosal gel	High	Moderate	Local tolerability and reproducible delivery
Ophthalmic gel or insert	Moderate to high	Moderate	Ocular safety and sterility
Liposomal injectable	High if renal exposure is reduced	Low to moderate	Manufacturing and toxicology complexity
Oral lipid formulation	High	Low without new chemistry	Poor permeability and prodrug competition
Long-acting depot	High in selected indications	Low	Dose loading, tissue safety, and release control
Pediatric liquid	Moderate	Moderate	Taste, stability, dosing accuracy, and limited market size

The highest near-term opportunity is a standardized topical or mucosal formulation for a defined viral indication. The highest value opportunity is a renal-sparing systemic product, but that path is more likely to depend on a prodrug or targeted delivery platform than on conventional excipients.

How does cidofovir compare with brincidofovir?

Cidofovir and brincidofovir address different product requirements.

Attribute	Cidofovir	Brincidofovir
Administration	Intravenous	Oral
Chemical type	Nucleotide phosphonate	Lipid-conjugated cidofovir prodrug
Primary commercial value	Established antiviral activity and hospital use	Improved oral delivery and systemic convenience
Renal toxicity	Major limitation	Developed to reduce cidofovir-associated renal toxicity
Excipient opportunity	Local delivery, topical systems, renal-sparing carriers	Oral formulation, stability, taste, and bioavailability optimization
Development model	Reformulation or repurposing	New chemical entity or prodrug lifecycle
Competitive risk	Generic and compounded alternatives	Patent, regulatory, and clinical differentiation requirements

Brincidofovir was approved by the FDA for treatment of smallpox in adults and pediatric patients, including neonates, infants, children, and pregnant or breastfeeding women, subject to the product labeling and indication in effect.[5,6] Its approval reduces the commercial attractiveness of an oral cidofovir formulation that does not provide a clear clinical or pharmacokinetic advantage.

What FDA regulatory status applies to cidofovir products?

The FDA-approved cidofovir product is an intravenous drug approved under an NDA for CMV retinitis in patients with AIDS.[1] A topical, ophthalmic, inhaled, oral, or depot cidofovir product would require a separate regulatory strategy.

Potential pathways include:

• An abbreviated or hybrid pathway for a materially equivalent parenteral product, where legally and scientifically available
• A new drug application for a new dosage form, indication, or delivery system
• A 505(b)(2) application relying partly on published literature or FDA findings for cidofovir
• A full development program if the formulation materially changes exposure, safety, or clinical use

A 505(b)(2) strategy may be relevant for a new topical or ophthalmic product if the sponsor can bridge the active ingredient and rely on existing cidofovir safety and pharmacology data. The extent of required clinical evidence would depend on the route, indication, exposure, and formulation differences.

What is the Orange Book status of cidofovir?

Cidofovir’s branded formulation has long been exposed to the expiration of historical composition and use patents. The commercial question is not simply whether the active ingredient is off patent. It is whether an applicant can obtain approval for a formulation with adequate stability, bioequivalence or clinical support, and manageable manufacturing economics.

For a new topical, ocular, or controlled-release formulation, patent protection could focus on:

• Excipient ratios
• pH and osmolality ranges
• Particle size
• Encapsulation efficiency
• Drug-release profiles
• Lesion-specific dosing
• Reduced systemic exposure
• Combination with hydration or renal-protective therapy
• Container-closure systems
• Manufacturing processes

Current Orange Book listings, discontinued-product records, and patent-term information should be reviewed before an investment or filing decision. Cidofovir is not a biologic, so biosimilar approval is not applicable.

When does cidofovir lose exclusivity, and what generic entry risks exist?

The principal active-ingredient and original-product exclusivity barriers are historical rather than prospective. Cidofovir was approved in 1996, and its early patent estate would generally have expired years ago, subject to patent-term adjustments, pediatric extensions, terminal disclaimers, and jurisdiction-specific rights.[1,7]

The remaining commercial barriers are more practical:

1. Small and irregular demand.
2. Renal toxicity and complex co-administration.
3. Hospital pharmacy handling requirements.
4. Limited approved indications.
5. Manufacturing economics for a low-volume injectable.
6. Potential difficulty securing a stable supply chain.
7. Limited incentive for multiple generic entrants.

A generic IV product could enter without overcoming the commercial weaknesses of cidofovir. It would still face a narrow market, procurement pressure, and the need to support sterile manufacturing. A new formulation can command stronger protection if it produces a clinically meaningful improvement, such as eliminating probenecid, reducing hydration, lowering nephrotoxicity, or enabling outpatient administration.

Are there Paragraph IV challenges or patent litigation affecting cidofovir?

Cidofovir’s key patent disputes are largely historical. No major current Paragraph IV litigation or active biosimilar dispute is central to the cidofovir market. Paragraph IV risk would become relevant if a sponsor obtained new patents covering a topical, ophthalmic, depot, nanoparticle, or renal-sparing formulation and a later applicant filed an ANDA or 505(b)(2) application challenging those claims.

Potential litigation targets would include:

• Drug product claims
• Formulation claims
• Manufacturing claims
• Stability claims
• Method-of-use claims
• Reduced-nephrotoxicity claims
• Combination claims involving probenecid or hydration

Method-of-use patents may be more commercially defensible than broad formulation claims when tied to a specific viral disease, patient population, dosing schedule, or route of administration. Broad excipient claims are vulnerable if prior art discloses the same polymer, vehicle, or pH range with another antiviral or nucleotide analogue.

What patent strategy is strongest for a new cidofovir product?

A layered patent estate is preferable to reliance on a single composition claim.

Core claim categories

• Cidofovir concentration and pH
• Defined excipient classes and ratios
• Particle size and encapsulation parameters
• Release kinetics
• Reduced renal exposure
• Specific tissue-targeting profiles
• Topical or mucosal indications
• Dosing schedules
• Combination treatment with probenecid
• Manufacturing and sterilization processes
• Primary packaging and stability

The strongest claims will connect a formulation variable to a measurable clinical or pharmacokinetic result. Examples include reduced urinary cidofovir exposure, increased lesion concentration, reduced dosing frequency, or improved ocular retention.

Geographic protection should prioritize the United States, European Union, Japan, Canada, Australia, and countries with meaningful CMV, mpox, HPV, or immunocompromised-patient populations. Manufacturing patents may be valuable in India, China, Ireland, Singapore, and other jurisdictions used for sterile or complex pharmaceutical production.

Which companies are challenging or competing with cidofovir?

Competition comes from several categories rather than from direct cidofovir generics alone.

Competitor category	Examples	Competitive effect
CMV antivirals	Ganciclovir, valganciclovir, foscarnet, letermovir	Limits demand for cidofovir in CMV
Smallpox countermeasures	Brincidofovir, tecovirimat	Reduces opportunity for systemic cidofovir in orthopoxvirus disease
Compounded cidofovir	Hospital and specialty-compounding pharmacies	Competes with topical commercial products
Local antiviral therapies	Disease-specific topical or intralesional treatments	Limits the addressable market for cidofovir reformulations
Generic sterile injectables	Potential cidofovir injection entrants	Increases price pressure
Drug-delivery companies	Liposomal, polymeric, and depot-platform developers	Provide enabling technologies for renal-sparing products

The most important commercial comparison is not between branded and generic cidofovir. It is between cidofovir and therapies that avoid intravenous administration, renal toxicity, or intensive monitoring.

What revenue exposure and market size support cidofovir reformulation?

Cidofovir is a niche product. Its market is constrained by the decline in AIDS-related CMV retinitis, the availability of alternative antivirals, toxicity concerns, and the limited number of patients treated under specialist supervision.

Revenue potential is more credible in a focused specialty market than in a broad primary-care antiviral market. The strongest commercial cases are:

• A topical product for a defined refractory viral lesion indication
• A mucosal product with superior retention and patient usability
• A renal-sparing systemic product for resistant CMV
• A pediatric or outpatient formulation that reduces infusion burden
• A product for an emergency preparedness or biodefense stockpile
• A formulation paired with a licensing deal for a delivery platform

A topical product could obtain premium pricing if it replaces inconsistent compounding and demonstrates superior lesion response. A systemic product must show a clear reduction in nephrotoxicity or administration burden to offset clinical development and manufacturing costs.

Key Takeaways

• Cidofovir’s approved formulation is a simple aqueous IV concentrate adjusted with sodium hydroxide and hydrochloric acid and diluted in 0.9% sodium chloride.
• The primary formulation problem is nephrotoxicity and poor tissue-selective delivery, not basic solubility.
• Topical, mucosal, ophthalmic, liposomal, and depot systems offer the clearest excipient-led opportunities.
• Oral delivery is difficult because cidofovir is highly polar and poorly permeable; brincidofovir demonstrates the stronger prodrug route.
• The original cidofovir patent barriers are historical. New commercial value would depend on formulation, method-of-use, manufacturing, or delivery patents.
• A standardized topical product could compete with compounded preparations through validated potency, stability, and usability.
• A systemic reformulation would need to reduce renal exposure, eliminate or reduce probenecid and hydration, or materially improve outpatient treatment.
• Cidofovir has no biosimilar pathway because it is a small-molecule antiviral.
• The most credible commercial strategy is a focused specialty product supported by a layered patent estate and a 505(b)(2) or other streamlined regulatory pathway where available.

FAQs About Cidofovir Excipients and Commercial Development

Can cidofovir be formulated as an oral tablet?

A conventional oral tablet is unlikely to provide adequate exposure because cidofovir has poor membrane permeability and low oral bioavailability. A prodrug or advanced delivery system would be more plausible than excipient optimization alone.

Is compounded topical cidofovir an FDA-approved product?

Compounded topical cidofovir preparations are not the same as an FDA-approved topical cidofovir drug product. Commercial development would require validated manufacturing, stability, dose uniformity, safety, and clinical evidence.

Can a cidofovir formulation eliminate probenecid?

A new formulation could seek to reduce the need for probenecid by lowering renal tubular exposure, altering distribution, or using a prodrug. That result would require clinical evidence and could support method-of-use and formulation patent claims.

What packaging is appropriate for cidofovir injection?

A sterile single-dose vial is consistent with the approved product. A ready-to-use bag or prefilled system would require separate compatibility, extractables, leachables, stability, particulate, and container-closure data.

Is cidofovir suitable for an emergency stockpile product?

Cidofovir may have strategic value for selected viral threats, but stockpile economics depend on shelf life, supply continuity, indication-specific guidance, and competition from approved countermeasures such as brincidofovir and tecovirimat.

References

1. U.S. Food and Drug Administration. (1996). Vistide (cidofovir) injection prescribing information. FDA.

2. Cihlar, T., & Chen, M. S. (1996). Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on these activities. Antimicrobial Agents and Chemotherapy, 40(1), 135-140.

3. Snoeck, R., Andrei, G., & De Clercq, E. (2002). Cidofovir in the treatment of DNA virus infections. Antiviral Chemistry & Chemotherapy, 13(6), 319-329.

4. U.S. Food and Drug Administration. (n.d.). Compounding and the FDA: Questions and answers. FDA.

5. U.S. Food and Drug Administration. (2021). Tembexa (brincidofovir) prescribing information. FDA.

6. Hostetler, K. Y. (2009). Synthesis and antiviral activity of a phospholipid prodrug of cidofovir. Antiviral Research, 82(3), A28.

7. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources. USPTO.